HDFC Pharma and Healthcare Fund Regular Growth is a Sector - Healthcare mutual fund scheme from HDFC Asset Management Co Ltd. The fund was launched on 4 October 2023 and is managed by Nikhil Mathur and Dhruv Muchhal. As of 15 October 2026, the fund has an AUM of ₹3,501.37 Cr and its latest NAV is ₹20.48. The fund has a Very High Risk risk rating.
The fund allows minimum SIP of ₹100 and lumpsum investment starting from ₹100.
The fund primarily invests in Healthcare and Basic Materials and its top holdings include Divi's Laboratories Ltd, Sun Pharmaceuticals Industries Ltd, Alkem Laboratories Ltd, Cipla Ltd, and Apollo Hospitals Enterprise Ltd. The fund has delivered 19.8% returns over the last 1 year, 26.9% annualised returns over 3 years, and 27.0% annualised returns since inception.
HDFC Pharma and Healthcare Fund Regular Growth may be suitable for investors looking for Sector - Healthcare and who are comfortable with Very High Risk risk.






